Recently, Dr. Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, led a delegation to visit Cholesgen to discuss their early-stage drug development collaboration. To date, the joint collaboration efforts in early-stage drug development have progressed smoothly and are delivering to plan. During the visit, AstraZeneca recognized the team for the project’s execution, as well as Cholesgen’s R&D capabilities and professional expertise and both parties reviewed the existing collaboration outcomes and discussed potential for further opportunities.

 近日，阿斯利康全球高级副总裁，心血管、肾病及代谢疾病早期研发负责人Regina Fritsche Danielson博士率团访问珂阑医药，就双方在早期药物开发领域的合作展开交流。目前双方在早期药物开发方面的联合合作进展顺利，按计划有序推进。

  访问期间，阿斯利康对项目执行情况、珂阑医药的研发实力与专业能力给予了认可；双方共同回顾了现有合作成果，并探讨了未来进一步深化合作的潜在机会。